Emeren Group Announces Preliminary 2023 Financials and 2024 Outlook
STAMFORD, Conn., Jan. 25, 2024 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today provided a preliminary unaudited overview of its key...
Reebelo encourages Aussies to make the switch to sustainable tech this New Year
Reebelo has been giving Australian consumers access to affordable, trustworthy and sustainable tech since 2020. MELBOURNE, Australia, Jan. 25, 2024 /PRNewswire/ -- Reebelo, the world's fastest growing and most trusted[1] online marketplace for...
Spielwarenmesse 2024 launches larger and to strong international interest
Unique diversity of products from newcomers and major brands 'Life's a Playground' – research, special area and presentations on leading topic Personalised networking opportunities and cool selfie-spots NUREMBERG, Germany, Jan. 25, 2024 /PRNewswire/...
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. Jiangsu Alphamab and 3D Medicines will receive a low double digit...
Cyrusher Unveils Exciting 2024 Development Plans: A New Era of Electric Adventure
LOGAN, Utah, Jan. 25, 2024 /PRNewswire/ -- Cyrusher, a leading manufacturer of electric mobility vehicles and other devices, recently revealed its 2024 development plan as a strategic move to reshape the landscape of electric exploration. Cyrusher...
Autohome Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results on February 6, 2024
BEIJING, Jan. 25, 2024 /PRNewswire/ -- Autohome Inc. (NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"), a leading online destination for automobile consumers in China, today announced that it will report its financial results for the fourth...
Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and...
CNOOC Limited Announces Its 2024 Business Strategy and Development Plan
HONG KONG, Jan. 25, 2024 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) today announces its business strategy and development plan for the year 2024. Continue to increase reserves and...